KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases (2019 - 2025)

Historic Current Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $2.4 million.

  • Esperion Therapeutics' Current Leases fell 1302.44% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 1302.44%. This contributed to the annual value of $2.7 million for FY2024, which is 7649.71% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Current Leases stood at $2.4 million, which was down 1302.44% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Current Leases peaked at $2.8 million during Q1 2025, and registered a low of $305000.0 during Q1 2023.
  • Its 5-year average for Current Leases is $1.8 million, with a median of $2.3 million in 2021.
  • Per our database at Business Quant, Esperion Therapeutics' Current Leases plummeted by 7493.84% in 2023 and then skyrocketed by 73245.9% in 2024.
  • Esperion Therapeutics' Current Leases (Quarter) stood at $1.4 million in 2021, then crashed by 72.41% to $384000.0 in 2022, then skyrocketed by 304.43% to $1.6 million in 2023, then surged by 76.5% to $2.7 million in 2024, then decreased by 13.02% to $2.4 million in 2025.
  • Its Current Leases stands at $2.4 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.